Chiasma to Present New Data from Two Phase 3 Trials, CHIASMA OPTIMAL and MPOWERED™, at ENDO 2021
-- One oral presentation and five late-breaking posters accepted -- NEEDHAM, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform …